|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
1,430,000,000 |
Market
Cap: |
107.49(B) |
Last
Volume: |
4,252,431 |
Avg
Vol: |
8,429,684 |
52
Week Range: |
$48.64 - $75.67 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 297 |
Guru Rank Value : 4.1 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
241,206 |
430,874 |
929,865 |
2,041,378 |
Total Sell Value |
$17,733,804 |
$29,055,549 |
$55,374,067 |
$104,875,147 |
Total People Sold |
8 |
10 |
11 |
13 |
Total Sell Transactions |
13 |
25 |
42 |
77 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Monson Jonathan |
SVP, Global Controller and CAO |
|
2022-07-01 |
4 |
D |
$38.01 |
$8,134 |
D/D |
(214) |
31,833 |
|
- |
|
Monson Jonathan |
SVP, Global Controller and CAO |
|
2022-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
728 |
32,047 |
|
- |
|
Carruthers Wendy |
EVP, Human Resources |
|
2022-06-24 |
4 |
AS |
$38.00 |
$285,000 |
D/D |
(7,500) |
132,413 |
|
9% |
|
Mirviss Jeffrey B. |
EVP&Pres, Periph Intervent |
|
2022-05-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
26 |
110,290 |
|
- |
|
Carruthers Wendy |
EVP, Human Resources |
|
2022-05-16 |
4 |
AS |
$39.43 |
$295,725 |
D/D |
(7,500) |
139,913 |
|
-4% |
|
Dockendorff Charles J |
Director |
|
2022-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,877 |
17,079 |
|
- |
|
Scanlon Meghan |
SVP,Pres,Urology Pelvic Health |
|
2022-05-01 |
4 |
D |
$42.11 |
$25,519 |
D/D |
(606) |
24,461 |
|
- |
|
Scanlon Meghan |
SVP,Pres,Urology Pelvic Health |
|
2022-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,062 |
25,067 |
|
- |
|
Mirviss Jeffrey B. |
EVP&Pres, Periph Intervent |
|
2022-04-20 |
4 |
AS |
$46.50 |
$448,493 |
D/D |
(9,645) |
110,316 |
|
-15% |
|
Mirviss Jeffrey B. |
EVP&Pres, Periph Intervent |
|
2022-04-19 |
4 |
AS |
$45.50 |
$500,000 |
D/D |
(10,989) |
119,961 |
|
-12% |
|
Carruthers Wendy |
EVP, Human Resources |
|
2022-04-14 |
4 |
AS |
$44.47 |
$333,518 |
D/D |
(7,500) |
147,413 |
|
-6% |
|
Eddy Jodi Euerle |
SVP, Chief Info & Digital Off. |
|
2022-04-01 |
4 |
AS |
$45.00 |
$125,055 |
D/D |
(2,779) |
23,263 |
|
-7% |
|
Olson Scott |
SVP & Pres, CRM, Diagnostics |
|
2022-04-01 |
4 |
AS |
$44.55 |
$31,185 |
D/D |
(700) |
14,518 |
|
-7% |
|
Butcher Arthur C |
EVP&Pres, Asia Pacific |
|
2022-03-29 |
4 |
AS |
$45.00 |
$462,105 |
D/D |
(10,269) |
30,278 |
|
-9% |
|
Butcher Arthur C |
EVP&Pres, Asia Pacific |
|
2022-03-29 |
4 |
OE |
$16.31 |
$88,253 |
D/D |
5,411 |
40,547 |
|
- |
|
Meredith Ian T |
EVP Global Chief Med Officer |
|
2022-03-28 |
4 |
AS |
$43.68 |
$287,764 |
D/D |
(6,588) |
28,082 |
|
-8% |
|
Mirviss Jeffrey B. |
EVP&Pres, Periph Intervent |
|
2022-03-22 |
4 |
AS |
$44.50 |
$500,002 |
D/D |
(11,236) |
130,950 |
|
-6% |
|
Carruthers Wendy |
EVP, Human Resources |
|
2022-03-15 |
4 |
AS |
$42.34 |
$317,587 |
D/D |
(7,500) |
154,913 |
|
-11% |
|
Fitzgerald Joseph Michael |
EVP & Pres, Cardiology |
|
2022-03-03 |
4 |
D |
$43.96 |
$78,205 |
D/D |
(1,779) |
217,871 |
|
- |
|
Fitzgerald Joseph Michael |
EVP & Pres, Cardiology |
|
2022-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,603 |
219,650 |
|
- |
|
Brennan Daniel J. |
EVP and CFO |
|
2022-03-02 |
4 |
AS |
$44.03 |
$485,650 |
D/D |
(11,029) |
264,290 |
|
-16% |
|
Pierce David A |
EVP Pres MedSurg |
|
2022-03-01 |
4 |
AS |
$43.94 |
$75,840 |
D/D |
(1,726) |
0 |
|
-13% |
|
Mirviss Jeffrey B. |
EVP&Pres, Periph Intervent |
|
2022-02-28 |
4 |
D |
$44.17 |
$27,562 |
D/D |
(624) |
142,186 |
|
- |
|
Mirviss Jeffrey B. |
EVP&Pres, Periph Intervent |
|
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,037 |
142,810 |
|
- |
|
Brown Vance R |
SVP, GC and Corp. Secretary |
|
2022-02-28 |
4 |
D |
$44.17 |
$13,251 |
D/D |
(300) |
32,755 |
|
- |
|
2518 Records found
|
|
Page 16 of 101 |
|
|